Comparative Pharmacology
Head-to-head clinical analysis: EVOCLIN versus SILVADENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOCLIN versus SILVADENE.
EVOCLIN vs SILVADENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to microbial DNA and proteins, inhibiting cell wall synthesis and cell division. The sulfadiazine component provides additional bacteriostatic action by competing with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase in folic acid synthesis.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
Apply a thin layer (approximately 1/16 inch) of 1% cream to the affected area once or twice daily. Use a sterile gloved hand. Reapply as needed to maintain coverage.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
The terminal elimination half-life of sulfadiazine is approximately 10-12 hours in patients with normal renal function. Silver has a very long biological half-life (weeks to months) due to tissue deposition.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Silver sulfadiazine applied topically results in minimal systemic absorption. The sulfadiazine component is primarily excreted renally (approximately 70% as unchanged drug and metabolites), with biliary/fecal excretion accounting for a small fraction (<10%). Silver is largely retained in tissues, not excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic